Jefferies Financial Group Lowers Reata Pharmaceuticals (NASDAQ:RETA) to Hold

Jefferies Financial Group downgraded shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Friday morning, MarketBeat Ratings reports. The firm currently has $172.50 target price on the stock, up from their previous target price of $104.00. Other equities analysts also […]

Related Keywords

China ,Manmeet Singh Soni ,Stifel Nicolaus ,Andrea Loewen ,Jefferies Financial Group ,International Assets Investment Management ,Barclays ,Cantor Fitzgerald ,Securities Exchange Commission ,Reata Pharmaceuticals Trading Down ,Hedge Funds Weigh In On Reata Pharmaceuticals ,Reata Pharmaceuticals ,Analyst Recommendations For Reata Pharmaceuticals ,China Universal Asset Management Co ,Advisor Group Holdings Inc ,Belpointe Asset Management ,Reata Pharmaceuticals Inc ,News Ratings For Reata Pharmaceuticals Daily ,Free Report ,Marketbeat Ratings ,Pharmaceuticals Trading Down ,Get Free Report ,Singh Soni ,Exchange Commission ,Asset Management ,Assets Investment Management ,Universal Asset Management ,Advisor Group Holdings ,Group Holdings ,Reata Pharmaceuticals Daily ,Nasdaq Reta ,Greta ,Medical ,Downgrade ,Jefferies Financial Group Inc ,